CereVasc, Inc. Appoints Tony Kingsley as President and Chief Executive Officer

Dan Levangie to transition to Chairman of the Board

BOSTON, Sept. 15, 2026 /PRNewswire/ -- CereVasc, Inc. today announced the appointment of Tony Kingsley as President and Chief Executive Officer. Dan Levangie, CereVasc's current President and CEO, will transition to Chairman of the Board, continuing to provide strategic guidance and support throughout the company's next phase of growth.

Kingsley brings extensive leadership experience and a strong track record of building and advancing innovative healthcare companies. As President and CEO, he will lead CereVasc's strategy and operations as the company prepares for commercial introduction of its breakthrough eShunt System.

"We are thrilled to welcome Tony to CereVasc," said Levangie. "His deep commercial leadership experience in neurology, strategic perspective and passion for advancing meaningful healthcare innovation make him an outstanding choice to lead the company forward. I am tremendously proud of what the CereVasc team has accomplished, and I look forward to supporting Tony and the organization in my new role as Chairman."

"I am honored and excited to join CereVasc at such an important moment in the company's journey," said Kingsley. "CereVasc has an exceptional team, a compelling vision and a deep commitment to improving patients' lives. I look forward to building on the strong foundation established under Dan's leadership and working with our employees, Board and partners to unlock the company's full potential."

During his tenure as President and CEO, Levangie helped establish CereVasc's position as an innovative leader in interventional neurosurgery, leading the company's evolution from an early-stage concept to a breakthrough alternative to conventional CSF shunting with more than 200 patients successfully treated worldwide. As Chairman, he will remain actively engaged with Kingsley, the Board and the leadership team to help ensure a smooth transition and continued momentum.

"Dan's vision and leadership have been instrumental in bringing CereVasc to this exciting stage, poised to transform the care of patients suffering from communicating hydrocephalus," said Kevin Conroy, Lead Independent Director of CereVasc, Inc. "We are grateful that the company will continue to benefit from his experience and insight as Chairman. With Tony stepping into the CEO role, we believe CereVasc is exceptionally well positioned for its next chapter."

Kingsley's appointment and Levangie's transition to Chairman are effective September 15, 2026.

About CereVasc, Inc.
Located in Massachusetts' healthcare hub, CereVasc, Inc. is a clinical-stage medical device company focused on developing novel, minimally invasive treatments for patients with neurological diseases. Its initial product, the eShunt System, employs an innovative percutaneous transvenous-transdural approach to the central nervous system and is intended to enable the first minimally invasive treatment for communicating hydrocephalus (CH). The patented eShunt System includes an endovascularly implantable cerebrospinal fluid shunt and delivery components designed to treat CH without invasive surgery. For additional information, please visit www.cerevasc.com.

Media Contact:
DJ Cass
CereVasc, Inc.
[email protected] 

SOURCE CereVasc, Inc.